Document is current
Any future updates will be listed below
-
Authors
Döhner, Hartmut https://orcid.org/0000-0003-2116-5536
Wei, Andrew H.
Löwenberg, Bob https://orcid.org/0000-0001-8982-5217
- License Information
-
More Information
Article History
Accepted: 29 March 2021
First Online: 18 May 2021
Competing interests
: H.D. has acted as an advisor for AbbVie, Agios, Amgen, Astellas, Astex Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Celgene, GEMoaB, Helsinn, Janssen, Jazz Pharmaceuticals, Novartis, Oxford Biomedica and Roche, and has received research funding from Agios, Amgen, Astellas, Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Novartis and Pfizer. A.W. has acted as an advisor for AbbVie, Agios, Amgen, Bristol Myers Squibb, Gilead, Janssen, Macrogenics, Novartis, Pfizer, Roche and Servier, has received research funding from AbbVie, Amgen, Astra Zeneca, Bristol Myers Squibb, Novartis and Servier, serves on speakers bureaus for AbbVie, Celgene and Novartis, and receives royalty payments from the Walter and Eliza Hall Institute of Medical Research related to venetoclax. B.L. has acted as an advisor for AbbVie, AIMM Therapeutics, Astellas, Catamaran Bio Inc., Bristol Myers Squibb, Celgene, Clear Creek Bio, F. Hoffmann La Roche, GEMoaB, Kronos Bio Inc and Oxford Biomedica, and holds shares in Frame Pharmaceuticals.
